VBIV VBI Vaccines Inc.

0  0%
Previous Close 0.79
Price To Book 0.89
Market Cap 77,045,463
Shares 97,661,887
Volume 76,030
Short Ratio
Av. Daily Volume 1,271,358

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a (Part B) to commence mid-2019.
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data met co-primary endpoints but missed key secondary endpoint.
Hepatitis B vaccine
Phase 2 trial to be initiated YE 2019.
Congenital Cytomegalovirus (CMV)
Phase 3 data due YE 2019.
Hepatitis B vaccine

Latest News

  1. VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
  2. Vbi Vaccines Inc (VBIV) CEO, President Jeff Baxter Bought $105,120 of Shares
  3. VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
  4. VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
  5. VBI Vaccines Announces Results of Annual General Meeting
  6. VBI Vaccines Sees Hammer Chart Pattern: Time to Buy?
  7. VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
  8. All You Need to Know About VBI Vaccines, Inc. (VBIV) Rating Upgrade to Buy
  9. VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Tops Revenue Estimates
  10. VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update
  11. VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  12. VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call
  13. VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
  14. VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
  15. VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop  
  16. VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
  17. VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
  18. VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients
  19. VBI Vaccines Appoints Blaine McKee to Board of Directors
  20. VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate